Ascentage Pharma Group Inc.
Clinical trials sponsored by Ascentage Pharma Group Inc., explained in plain language.
-
Promising combo for advanced cancers halted early
Disease control TerminatedThis study tested a combination of two drugs, APG-1387 and toripalimab, in 40 people with advanced solid tumors like colorectal, nasopharyngeal, and lung cancer. The goal was to find a safe dose and see if the combo could control the disease. The trial was terminated early, so re…
Phase: PHASE1, PHASE2 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated May 17, 2026 02:41 UTC
-
Experimental combo for tough pancreatic cancer shows early promise
Disease control TerminatedThis study tested a new drug called APG-1387 combined with standard chemotherapy (nab-paclitaxel and gemcitabine) in people with advanced pancreatic cancer that had stopped responding to treatment. The goal was to find the safest dose and see if the combination could shrink tumor…
Phase: PHASE1, PHASE2 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC